Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Researchers found that blocking immune-suppressing cells allows chemotherapy to destroy prostate tumors in mouse models, achieving near complete remission. This novel combination therapy may have broader applications for other cancer types due to its effectiveness against metastatic and unresponsive cancers.
The ASCENDE-RT1 trial found that permanent radioactive implants (brachytherapy) reduced prostate cancer recurrence by 50% at five years compared to dose-escalated external beam radiotherapy. LDR-PB also showed an overall survival advantage, but with more urinary side effects.
Researchers found that MR tractography can accurately assess prostate cancer treatment response to androgen deprivation and radiation therapy. Higher tract densities indicate gland shrinkage and subsequent fibrosis after therapy.
A major trial has shown that olaparib can effectively treat advanced prostate cancer in men with defects in DNA repair genes. The results suggest that up to 30% of patients with terminal prostate cancer may benefit from the drug, which could become a treatment option if replication is confirmed in further trials.
Multiparametric MRI and ultrasound fusion enables targeted biopsies of high-suspicion foci with increased diagnostic accuracy for prostate cancer. For patients on active surveillance, this method better characterizes the prostate gland and detects higher-grade disease.
A research team led by Charles Sawyers and Howard Scher discovered novel antiandrogen enzalutamide, which extended survival among patients with metastatic castration-resistant prostate cancer. The AACR Team Science Award recognizes the team's innovative work in advancing cancer research.
A recent study found that obesity substantially increases prostate cancer risk in African-American men, while having a moderate effect on non-Hispanic white men. The research suggests that obesity may play an important role in the 'African-American race effect' on prostate cancer disparities.
A new Northwestern Medicine study found that walking at an easy pace for three hours a week improves prostate cancer survivors' fatigue, depression, and body weight issues. Non-vigorous walking also showed benefits in these areas, with brisk walking potentially leading to similar improvements.
Studies published in Journal of Cancer Survivorship found that walking three hours a week can improve hormone functioning and vitality in prostate cancer survivors. Regular physical activity also reduces symptoms of chemotherapy-induced peripheral neuropathy in colorectal cancer survivors, improving quality of life.
Research found a significant association between obesity and increased prostate cancer risk in African American men, with the risk growing nearly four times as body-mass index (BMI) increased. Obesity was also linked to a higher risk of aggressive disease and prostate cancer death among this population.
Researchers have discovered a protein biomarker that may indicate the presence of more aggressive prostate cancer. The biomarker, Runx2 phosphorylation, is closely associated with aggressive disease and has the potential to be a new drug target.
Researchers at the University of York have found a potential new treatment for organ-confined prostate cancer using low-temperature plasmas. The study, published in the British Journal of Cancer, suggests LTPs may be a viable alternative to current radiotherapy and photodynamic therapy treatments.
Researchers mapped genetic changes in tumor samples from 10 men with prostate cancer, revealing a common ancestral cell and shared gene faults. The study provides insight into how prostate cancer spreads and evolves, potentially leading to new treatment targets and personalized approaches.
A new study found that cells within metastases from prostate tumors can migrate to other body parts and form new sites of spread on their own. This challenges the long-held belief that cells with metastatic potential originate solely from the original tumor site.
A study published in JAMA Oncology found that high fitness levels in midlife were associated with a lower risk of lung and colorectal cancer. High fitness also reduced the risk of death from these cancers, as well as cardiovascular disease death among men diagnosed with cancer.
Researchers found delayed radiation therapy offers no protective benefit and may increase risk of complications, contradicting the long-held view. Adjuvant therapy soon after prostate removal is effective in curing patients with low-grade disease.
Implementing video-based decision aids in urology led to fewer elective surgeries for benign prostatic hyperplasia and localized prostate cancer. Rates of surgical intervention declined by 32% for treated BPH patients and 27% for localized prostate cancer patients.
Researchers found that vitamin D supplements slowed tumor growth and reduced inflammation in men with low-grade prostate cancer. The study suggests that vitamin D may improve treatment outcomes for these patients by reducing the need for aggressive treatments.
Washington State University researchers have discovered a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings suggest that a potential new anti-cancer drug could be developed to target this process.
Researchers developed a nanotechnology-based method to assess prostate cancer risk, enabling doctors to identify aggressive forms of the disease and tailor treatment recommendations. The study's findings suggest that this approach may improve patient outcomes by minimizing side effects.
A recent study defines a distinct subtype of aggressive prostate cancer marked by MAP3K7 and CHD1 gene loss, accounting for 10% of all cases and 25% of fatal outcomes. Researchers used stem-cell models to show that these genetic changes disrupt healthy tissue formation, leading to hybrid cells with aggressive characteristics.
A new study from NYU Langone Medical Center found that over 40% of low-risk prostate and breast cancer patients in certain US regions received inappropriate tests. The research suggests that regional culture and infrastructure play a significant role in the use of imaging tests, with some areas exhibiting more appropriate use than others.
Scientists at IRB Barcelona will study protein motions to identify new sites for drug targeting in prostate cancer. The project aims to unravel the connections between distant points of a protein, which could transform the field of drug discovery.
A study published in JAMA Oncology found high rates of inappropriate imaging for both prostate cancer and breast cancer, suggesting that regional culture and infrastructure play a role in health care utilization patterns. The researchers estimated that 30% of healthcare resources in the US do not improve patient health.
A family history of prostate cancer in first-degree relatives increases breast cancer risk by 14%, according to a study of 78,171 women. Women with both breast and prostate cancer histories face an almost 2-fold increase in breast cancer risk
New research shows that non-cancerous prostate cells with genetic mutations can develop into cancer, potentially explaining why prostate cancer often has multiple genetically different tumours. This discovery could lead to a rethink of treatment strategies and improve outcomes for men with the disease.
A study by the University of Exeter found that black men are less likely to opt for prostate cancer investigation due to fear and perception of severe complications. The research suggests that proactive discussion with doctors and targeted education may help address this issue.
A comprehensive, population-based regional health care management program for men with prostate cancer has led to improved outcomes. The program includes safety-net screening programs, improved surgical procedures, and enhanced drug management, resulting in lower rates of blood loss and osteoporosis-related complications.
A case-control study of over 180,000 men found that men with testicular cancer have a higher incidence of prostate cancer compared to those without a history of the disease. The study revealed a significant increase in aggressive prostate cancers among men with testicular cancer.
A retrospective analysis of 87,500 men treated for prostate cancer found a notable increase in intermediate- and high-risk cases between 2011 and 2013. This trend could lead to 1,400 additional prostate cancer deaths per year if confirmed through further research.
A study of 945 patients with intermediate-risk prostate cancer found nearly four-fold higher mortality risk within 15 years compared to low-risk patients. The analysis suggests that active surveillance may not be suitable for all intermediate-risk patients, emphasizing the need for personalized treatment approaches.
A small prospective study found no significant difference in treatment outcomes between patients with AR-V7-positive and -negative metastatic castration-resistant prostate cancer who received taxane chemotherapy. PSA responses were achieved in 41% of both groups.
Men with favorable intermediate-risk prostate cancer may be candidates for active surveillance, with no significantly increased risk of death compared to those with low-risk PC. The study found that the absolute estimates of PC-specific mortality were less than one percent in men with both low-risk and favorable intermediate-risk PC.
Keck Medicine researchers found that GPR158 promotes prostate cancer cell growth and is associated with neuroendocrine transdifferentiation, leading to tumor progression. Elevated expression of GPR158 is linked to recurrence in prostate cancer patients.
A Purdue University study found that a combination of low doses of metformin and gene inhibitor BI2536 can successfully halt the growth of late-stage prostate cancer tumors, potentially prolonging patients' lives. The treatment promotes self-destruction of cancer cells and prevents androgen synthesis.
Researchers at Ohio State University found that androgen receptor activates different genes when bound to antiandrogens, suggesting new targets for prostate cancer treatment. Antiandrogen response elements were discovered, which activate oncogenes relevant to tumor progression.
A study of over 1,000 men found that targeted fusion-guided biopsy is more effective in detecting high-risk prostate cancer than standard biopsy. This method combines MRI and ultrasound images to pinpoint suspicious areas and diagnose cancers with greater accuracy.
A targeted magnetic resonance/ultrasound fusion biopsy detected more high-risk prostate cancers and fewer low-risk cancers compared to standard biopsy. The study found that adding standard biopsy to targeted biopsy provided limited benefits in detecting additional high-risk tumors.
Patients with a history of smoking have increased risks of cancer relapse, side effects, and death from prostate cancer, according to a study published in BJU International. Smoking negatively affects prostate cancer health outcomes, particularly when treated with radiotherapy.
The Cleveland Clinic has received a $1 million grant to advance the treatment of lethal prostate cancer by identifying genetic biomarkers. The research aims to detect treatment-resistant prostate cancer at an early stage, improving treatment outcomes for patients.
Researchers at Oregon State University have identified sulforaphane's ability to selectively kill cancer cells and alter gene expression in metasticized prostate cancer. The compound may work alongside existing approaches to treat advanced prostate cancer, with potential for therapeutic value.
Researchers at Huntsman Cancer Institute have developed a new tool to estimate prostate cancer risk based on family history, which can help clinicians decide whether a PSA test is appropriate. The study found that two-thirds of Utah men have some increased risk of developing prostate cancer due to their family history.
A new study found that high-dose testosterone therapy can suppress advanced prostate cancers and reverse resistance to testosterone-blocking drugs. Seven of the 14 men showed a significant decrease in PSA levels, while four stayed on testosterone therapy for up to 24 months with continued low PSA levels.
A novel imaging technique called restriction spectrum imaging-MRI (RSI-MRI) has been developed to improve the accuracy of prostate cancer detection. RSI-MRI corrects for magnetic field distortions and focuses on water diffusion within tumor cells, providing a more refined sense of the tumor's extent.
A new study found that adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate cancer, reducing cancer deaths by nearly 50 percent. The treatment was also associated with fewer deaths from any cause.
Researchers found that SIRT1 enzyme loss drives early prostate cancer formation in mouse models. The study suggests SIRT1 may be a target for prostate cancer prevention.
Researchers discovered a protein called BAZ2A that influences epigenetic patterns in prostate cancer cells, leading to increased malignancy and tumor growth. High levels of BAZ2A expression were linked to more advanced tumors, metastases, and poor patient outcomes.
Researchers at Georgetown University Medical Center show that YK-4-279 prevents tumor growth and spread in mice with prostate cancer harboring a common chromosomal abnormality. The agent targets the ETS fusion, producing new genes that push cancer cells to become more aggressive.
A new study published in European Urology has found that androgen deprivation therapy (ADT) is associated with decreased survival in men with localized prostate cancer, particularly those with longer life expectancies. The research highlights the need to reconsider the use of ADT as a primary treatment for low-risk or localized cancers.
A study found that prescriptions for bisphosphonates remain low even among men at high risk of fractures on androgen deprivation therapy. The study suggests limited awareness among clinicians about optimal bone health management, particularly in men with prior osteoporosis or fragility fracture.
The Prolaris test could save the healthcare system $6 billion over 10 years by reducing costs and improving health outcomes. The test improves health outcomes, reduces healthcare costs, and aids physicians in providing clinical care for their patients.
Researchers have found that blocking the CCR5 receptor with an HIV drug can significantly reduce metastasis to the bone in prostate cancer. This breakthrough suggests a potential new treatment approach for patients with advanced prostate cancer.
Conventional treatments such as surgery and radiotherapy are less effective in prostate cancer patients carrying BRCA mutations, resulting in lower survival rates. The study suggests that targeted therapy, like PARP inhibitors, may be a more suitable option for these patients.
Researchers at UC Davis found that diets rich in whole walnuts or walnut oil slowed prostate cancer growth in mice. The walnut diet also reduced levels of the hormone IGF-1, which had been previously implicated in both prostate and breast cancer.
Researchers developed a genetic test to identify men at highest risk of prostate cancer recurrence after localized treatment. The test analyzes biopsy tissue and tumor oxygen content to predict disease return with 80% accuracy, enabling personalized treatment plans.
A new study shows a novel molecular imaging drug is effective in detecting early prostate cancer in soft tissue, lymph nodes, and bone. The drug, Tc-99m MIP-1404, has favorable pharmacokinetics and biodistribution, representing a breakthrough in prostate cancer imaging.
A molecular breakthrough has identified a compound that can inhibit the activity of SRPK1, a molecule key to tumor formation and blood vessel creation. This process is essential for cancer cell survival and multiplication.
Researchers at UT Arlington are developing tissue-engineered artificial lymph nodes that can attract prostate cancer cells, allowing for more targeted treatments and potentially longer patient survival. The technology, led by Liping Tang, could also help identify the biological signals that enable cancer to migrate throughout the body.
A recent study found that androgen deprivation therapy (ADT) increases the risk of heart-related deaths in men with congestive heart failure or prior heart attacks. The study analyzed data from 5,077 men with prostate cancer, revealing a 3.3-times increased risk of heart-related deaths in this subgroup.
Researchers have developed a device that can detect markers of kidney disease and prostate cancer in urine samples, offering instant results and potentially higher accuracy. The device uses DNA sequences to latch onto disease markers, allowing for early detection at ultra-low concentrations.